For the good of the patient: Silica from Evonik in the pharmaceutical industry
Many challenges – one solution: Fumed and precipitated silica from Evonik are some of the most important and highly used pharmaceutical excipients. Whether you manufacture medicines for solid, semi-solid or liquid dosing, we support you at every stage of product development.
Purity and reliability of raw materials are just two of the many challenges you face as a manufacturer of pharmaceutical products. If high-speed tablet and capsule production equipment, for example, is to run smoothly, the starting materials need to display optimum flow behavior. This is where our silica products come in: As flow aid, they ensure uniform active ingredient content in every tablet or capsule and increase production throughput.
And silica from Evonik can do much more: They can be used to reduce tablet weight without impacting stability. In pharmaceutical creams or viscous gels, they are used as thickening agents. Guaranteeing equal distribution of the active ingredient, these thickening and stabilizing properties are also beneficial when manufacturing active ingredient patches.
Evonik offers a broad portfolio of silica products for the pharmaceutical industry based on more than five decades of experience. Together, we will find the ideal system solutions to make your products even more successful. You can find more information on our portfolio in our Produktfinder.
Benefits of silica from Evonik for the pharmaceutical industry
- Stabilization of solid dispersions
- Versatile carrier for liquid or poorly soluble active pharmaceutical ingredients (API)
- Versatile auxiliary material for orally disintegrating tablets (ODT)
- Adjustment of rheology in semi-solid medications
- Improved dissolution of individual active ingredients
Evonik Silica is a multi-purpose raw material that can reduce complexity when handling raw materials
Video - Tableting with Moisture-Activated Dry Granulation
Silica from Evonik Regulatory Information
All AEROSIL® Pharma grades are manufactured according to IPEC GMP guidelines for bulk pharmaceutical excipients. Every lot is tested and certified according to compendial methods.
Compendial Compliance of Silica Products
|
Product
|
USP/NF
|
Ph. EUR.
|
JP
|
IP
|
|
AEROSIL® 200 Pharma
|
Colloidal silicon dioxide
|
Silica, colloidal anhydrous
|
Light anhydrous silicic acid
|
Silicon dioxide
|
|
AEROSIL® 300 Pharma
|
Colloidal silicon dioxide
|
Silica, colloidal anhydrous
|
Light anhydrous silicic acid
|
|
|
AEROPERL® 300 Pharma
|
Colloidal silicon dioxide
|
Silica, colloidal anhydrous
|
*
|
|
|
AEROSIL® R 972 Pharma
|
Hydrophobic colloidal silica
|
Silica, hydrophobic colloidal
|
No monograph
|
|
|
SIPERNAT® 160 PQ
|
Silicon dioxide
|
Silica colloidal hydrated
|
|
|
|
RXCIPIENTS® FM 1000
|
Calcium silicate
|
No monograph for calcium silicates.
EMA accepts compliance to USP/NF monographs for products for which no Ph. Eur. monograph exists |
|
|
|
ZEOPHARM® 600
|
Calcium silicate
|
No monograph for calcium silicates.
EMA accepts compliance to USP/NF monographs for products for which no Ph. Eur. monograph exists |
|
|
|
ZEOPHARM® 250
|
Calcium silicate
|
No monograph for calcium silicates.
EMA accepts compliance to USP/NF monographs for products for which no Ph. Eur. monograph exists |
|
|
* Granulated AEROPERL® 300 Pharma does not fulfill the JP "Volume Test" due to its high bulk density